Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers

Pediatric HIV/AIDS Cohort Study (PHACS)

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objectives: We evaluated the potential cardiac effects of in-utero exposures to antiretroviral drugs in HIV-exposed but uninfected (HEU) children. Design and methods: We compared echocardiographic parameters of left ventricular function (ejection fraction, fractional shortening, and stress-velocity index) and structure (left ventricular dimension, posterior wall/septal thickness, mass, thickness-todimension ratio, and wall stress) (expressed as Z-scores to account for age and body surface area) between HEU and HIV-unexposed cohorts from the Pediatric HIV/AIDS Cohort Study's Surveillance Monitoring for ART Toxicities study. Within the HEU group, we investigated the associations between the echocardiographic Z-scores and in-utero exposures to maternal antiretroviral drugs . Results: There were no significant differences in echocardiographic Z-scores between 417HEUand 98 HIV-unexposed children aged 2-7 years. Restricting the analysis toHEU children, first-trimester exposures to combination antiretroviral therapy (a regimen including at least three antiretroviral drugs) and to certain specific antiretroviral drugs were associated with significantly lower stress-velocity Z-scores (mean decreases of 0.22-0.40 SDs). Exposure to combination antiretroviral therapy was also associated with lower left ventricular dimension Z-scores (mean decrease of 0.44 SD). First-trimester exposure to combination antiretroviral therapy was associated with higher mean left ventricular posterior wall thickness and lower mean left ventricular wall stress Z-scores . Conclusion: There was no evidence of significant cardiac toxicity of perinatal combination antiretroviral therapy exposure in HEU children. Subclinical differences in left ventricular structure and function with specific in-utero antiretroviral exposures indicate the need for a longitudinal cardiac study in HEU children to assess long-term cardiac risk and cardiac monitoring recommendations .

Original languageEnglish (US)
Pages (from-to)91-100
Number of pages10
JournalAIDS
Volume29
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Mothers
HIV
First Pregnancy Trimester
Therapeutics
Left Ventricular Function
Pharmaceutical Preparations
Implosive Therapy
Maternal Exposure
Body Surface Area
Stroke Volume
Longitudinal Studies
Acquired Immunodeficiency Syndrome
Cohort Studies
Pediatrics

Keywords

  • Antiretroviral drugs
  • Cardiac
  • HIV
  • Pediatrics
  • Toxicity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers. / Pediatric HIV/AIDS Cohort Study (PHACS).

In: AIDS, Vol. 29, No. 1, 2015, p. 91-100.

Research output: Contribution to journalArticle

Pediatric HIV/AIDS Cohort Study (PHACS). / Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers. In: AIDS. 2015 ; Vol. 29, No. 1. pp. 91-100.
@article{c14552d55f584550b92c4fd89c11edb6,
title = "Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers",
abstract = "Objectives: We evaluated the potential cardiac effects of in-utero exposures to antiretroviral drugs in HIV-exposed but uninfected (HEU) children. Design and methods: We compared echocardiographic parameters of left ventricular function (ejection fraction, fractional shortening, and stress-velocity index) and structure (left ventricular dimension, posterior wall/septal thickness, mass, thickness-todimension ratio, and wall stress) (expressed as Z-scores to account for age and body surface area) between HEU and HIV-unexposed cohorts from the Pediatric HIV/AIDS Cohort Study's Surveillance Monitoring for ART Toxicities study. Within the HEU group, we investigated the associations between the echocardiographic Z-scores and in-utero exposures to maternal antiretroviral drugs . Results: There were no significant differences in echocardiographic Z-scores between 417HEUand 98 HIV-unexposed children aged 2-7 years. Restricting the analysis toHEU children, first-trimester exposures to combination antiretroviral therapy (a regimen including at least three antiretroviral drugs) and to certain specific antiretroviral drugs were associated with significantly lower stress-velocity Z-scores (mean decreases of 0.22-0.40 SDs). Exposure to combination antiretroviral therapy was also associated with lower left ventricular dimension Z-scores (mean decrease of 0.44 SD). First-trimester exposure to combination antiretroviral therapy was associated with higher mean left ventricular posterior wall thickness and lower mean left ventricular wall stress Z-scores . Conclusion: There was no evidence of significant cardiac toxicity of perinatal combination antiretroviral therapy exposure in HEU children. Subclinical differences in left ventricular structure and function with specific in-utero antiretroviral exposures indicate the need for a longitudinal cardiac study in HEU children to assess long-term cardiac risk and cardiac monitoring recommendations .",
keywords = "Antiretroviral drugs, Cardiac, HIV, Pediatrics, Toxicity",
author = "{Pediatric HIV/AIDS Cohort Study (PHACS)} and Lipshultz, {Steven E} and Williams, {Paige L.} and Bret Zeldow and Wilkinson, {James D.} and Rich, {Kenneth C.} and {Van Dyke}, {Russell B.} and Seage, {George R.} and Dooley, {Laurie B.} and Kaltman, {Jonathan R.} and Siberry, {George K.} and Mofenson, {Lynne M.} and Shearer, {William T.} and Colan, {Steven D.} and Mary Paul and Norma Cooper and Lynette Harris and Murli Purswani and Emma Stuard and Anna Cintron and Ana Puga and Dia Cooley and Doyle Patton and Deyana Leon and Richard Rutstein and Carol Vincent and Nancy Silverman and Ram Yogev and Sanders, {Margaret Ann} and Kathleen Malee and Scott Hunter and Andrew Wiznia and Marlene Burey and Molly Nozyce and William Borkowsky and Sandra Deygoo and Helen Rozelman and Katherine Knapp and Kim Allison and Megan Wilkins and Midnela Acevedo-Flores and Lourdes Angeli-Nieves and Vivian Olivera and Hermann Mendez and Ava Dennie and Susan Bewley and Sharon Nachman and Margaret Oliver and Karen Craig and Patricia Sirois and Scott, {Gwendolyn B}",
year = "2015",
doi = "10.1097/QAD.0000000000000499",
language = "English (US)",
volume = "29",
pages = "91--100",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers

AU - Pediatric HIV/AIDS Cohort Study (PHACS)

AU - Lipshultz, Steven E

AU - Williams, Paige L.

AU - Zeldow, Bret

AU - Wilkinson, James D.

AU - Rich, Kenneth C.

AU - Van Dyke, Russell B.

AU - Seage, George R.

AU - Dooley, Laurie B.

AU - Kaltman, Jonathan R.

AU - Siberry, George K.

AU - Mofenson, Lynne M.

AU - Shearer, William T.

AU - Colan, Steven D.

AU - Paul, Mary

AU - Cooper, Norma

AU - Harris, Lynette

AU - Purswani, Murli

AU - Stuard, Emma

AU - Cintron, Anna

AU - Puga, Ana

AU - Cooley, Dia

AU - Patton, Doyle

AU - Leon, Deyana

AU - Rutstein, Richard

AU - Vincent, Carol

AU - Silverman, Nancy

AU - Yogev, Ram

AU - Sanders, Margaret Ann

AU - Malee, Kathleen

AU - Hunter, Scott

AU - Wiznia, Andrew

AU - Burey, Marlene

AU - Nozyce, Molly

AU - Borkowsky, William

AU - Deygoo, Sandra

AU - Rozelman, Helen

AU - Knapp, Katherine

AU - Allison, Kim

AU - Wilkins, Megan

AU - Acevedo-Flores, Midnela

AU - Angeli-Nieves, Lourdes

AU - Olivera, Vivian

AU - Mendez, Hermann

AU - Dennie, Ava

AU - Bewley, Susan

AU - Nachman, Sharon

AU - Oliver, Margaret

AU - Craig, Karen

AU - Sirois, Patricia

AU - Scott, Gwendolyn B

PY - 2015

Y1 - 2015

N2 - Objectives: We evaluated the potential cardiac effects of in-utero exposures to antiretroviral drugs in HIV-exposed but uninfected (HEU) children. Design and methods: We compared echocardiographic parameters of left ventricular function (ejection fraction, fractional shortening, and stress-velocity index) and structure (left ventricular dimension, posterior wall/septal thickness, mass, thickness-todimension ratio, and wall stress) (expressed as Z-scores to account for age and body surface area) between HEU and HIV-unexposed cohorts from the Pediatric HIV/AIDS Cohort Study's Surveillance Monitoring for ART Toxicities study. Within the HEU group, we investigated the associations between the echocardiographic Z-scores and in-utero exposures to maternal antiretroviral drugs . Results: There were no significant differences in echocardiographic Z-scores between 417HEUand 98 HIV-unexposed children aged 2-7 years. Restricting the analysis toHEU children, first-trimester exposures to combination antiretroviral therapy (a regimen including at least three antiretroviral drugs) and to certain specific antiretroviral drugs were associated with significantly lower stress-velocity Z-scores (mean decreases of 0.22-0.40 SDs). Exposure to combination antiretroviral therapy was also associated with lower left ventricular dimension Z-scores (mean decrease of 0.44 SD). First-trimester exposure to combination antiretroviral therapy was associated with higher mean left ventricular posterior wall thickness and lower mean left ventricular wall stress Z-scores . Conclusion: There was no evidence of significant cardiac toxicity of perinatal combination antiretroviral therapy exposure in HEU children. Subclinical differences in left ventricular structure and function with specific in-utero antiretroviral exposures indicate the need for a longitudinal cardiac study in HEU children to assess long-term cardiac risk and cardiac monitoring recommendations .

AB - Objectives: We evaluated the potential cardiac effects of in-utero exposures to antiretroviral drugs in HIV-exposed but uninfected (HEU) children. Design and methods: We compared echocardiographic parameters of left ventricular function (ejection fraction, fractional shortening, and stress-velocity index) and structure (left ventricular dimension, posterior wall/septal thickness, mass, thickness-todimension ratio, and wall stress) (expressed as Z-scores to account for age and body surface area) between HEU and HIV-unexposed cohorts from the Pediatric HIV/AIDS Cohort Study's Surveillance Monitoring for ART Toxicities study. Within the HEU group, we investigated the associations between the echocardiographic Z-scores and in-utero exposures to maternal antiretroviral drugs . Results: There were no significant differences in echocardiographic Z-scores between 417HEUand 98 HIV-unexposed children aged 2-7 years. Restricting the analysis toHEU children, first-trimester exposures to combination antiretroviral therapy (a regimen including at least three antiretroviral drugs) and to certain specific antiretroviral drugs were associated with significantly lower stress-velocity Z-scores (mean decreases of 0.22-0.40 SDs). Exposure to combination antiretroviral therapy was also associated with lower left ventricular dimension Z-scores (mean decrease of 0.44 SD). First-trimester exposure to combination antiretroviral therapy was associated with higher mean left ventricular posterior wall thickness and lower mean left ventricular wall stress Z-scores . Conclusion: There was no evidence of significant cardiac toxicity of perinatal combination antiretroviral therapy exposure in HEU children. Subclinical differences in left ventricular structure and function with specific in-utero antiretroviral exposures indicate the need for a longitudinal cardiac study in HEU children to assess long-term cardiac risk and cardiac monitoring recommendations .

KW - Antiretroviral drugs

KW - Cardiac

KW - HIV

KW - Pediatrics

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84928011688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928011688&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000000499

DO - 10.1097/QAD.0000000000000499

M3 - Article

C2 - 25562493

AN - SCOPUS:84928011688

VL - 29

SP - 91

EP - 100

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 1

ER -